|05/11/17||Capnia Provides Corporate Update and Reports First Quarter 2017 Financial Results|
|Completed merger with Essentialis, Inc. and concurrent financing of $10 million
New company name, Soleno Therapeutics, Inc., to reflect new strategic focus on rare disease therapeutics; stock to trade under NASDAQ ticker symbol “SLNO”
Scientific advice being obtained from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the development of lead product candidate, Diazoxide Choline Controlled-Release (DCCR) in Prader-Willi syndrome (PWS)
Company expect... |
|03/15/17||Capnia Reports Fourth Quarter and Full Year 2016 Financial Results|
|REDWOOD CITY, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced financial results for the fourth quarter and twelve months ended December 31, 2016.
“During the fourth quarter, we embarked on a bold new strategic direction for our Company by signing a definitive agreement to merge with Essentialis, creating a dynamic new organization dedicated to dev... |
|03/08/17||Capnia Completes Merger with Essentialis Creating Rare Disease Therapeutics Company|
|Lead Clinical Asset Entering Phase II/III Development in 2017 for the Treatment of Prader-Willi Syndrome
Raises $10 Million in Concurrent Financing; Cash Runway Through Key Milestones
REDWOOD CITY, Calif., March 08, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), focused on the development and commercialization of novel therapeutics for the treatment of rare diseases, today announced that it has completed its previously-announced merger with privately-held Essentialis, Inc. effective M... |
|02/07/17||Capnia to Present at the 19th Annual BIO CEO & Investor Conference|
|REDWOOD CITY, Calif., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the 19th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2017 at 8:00 AM ET at the Waldorf Astoria Hotel in New York City.
The presentation will be webcast live ... |